• The orphan nuclear receptor TLX regulates hippocampal transcriptome changes induced by IL-1β 

  Ó Léime, Ciarán S.; Hoban, Alan E.; Hueston, Cara M.; Stilling, Roman; Moloney, Gerard; Cryan, John F.; Nolan, Yvonne M. (Elsevier, 2018-03-05)

  TLX is an orphan nuclear receptor highly expressed within neural progenitor cells (NPCs) in the hippocampus where is regulates proliferation. Inflammation has been shown to have negative effects on hippocampal function as ...
• Innovative strategies for teaching anatomy to dental students 

  Lone, Mutahira (University College Cork, 2018)

  Anatomy education is an integral component of the undergraduate and postgraduate dental curriculum. A detailed understanding of anatomy is a pre-requisite before examination, diagnosis and clinical treatment of patients ...
• Inhibition of miR-181a promotes midbrain neuronal growth through a Smad1/5-dependent mechanism: implications for Parkinson’s disease 

  Hegarty, Shane V.; Sullivan, Aideen M.; O'Keeffe, Gerard W. (Portland Press, 2018)

  Parkinson’s disease (PD) is the second most common neurodegenerative disease, and is characterized by the progressive degeneration of nigrostriatal dopaminergic (DA) neurons. Current PD treatments are symptomatic, wear off ...
• Faecal microRNAs: indicators of imbalance at the host-microbe interface? 

  Moloney, Gerard M.; Viola, Maria F.; Hoban, Alan E.; Dinan, Timothy G.; Cryan, John F. (Wageningen Academic Publishers, 2017-12-21)

  The enteric microbiota is characterised by a balance and composition that is unique to the host. It is important to understand the mechanisms through which the host can maintain the composition of the gut microbiota. ...
• Kynurenine pathway metabolism and neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy 

  Allen, Andrew P.; Naughton, M.; Dowling, J.; Walsh, A.; O'Shea, R.; Shorten, George D.; Scott, Lucinda V.; McLoughlin, D. M.; Cryan, John F.; Clarke, Gerard; Dinan, Timothy G. (Elsevier, 2018-02-10)

  Current first-line antidepressants can take weeks or months to decrease depressive symptoms. Low dose ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, shows potential for a more rapid antidepressant effect, ...

View more